CLINICAL_TRIALS ClinicalTrials.gov record update

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06093841
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:51.814107+00:00
Published At: 2025-02-11T00:00:00+00:00
Record Updated At: 2025-02-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, Large B-Cell, Diffuse", "Follicular Lymphoma Grade 3B", "High-grade B-cell Lymphoma", "Mediastinal B-Cell Diffuse Large Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-11"
protocolSection.identificationModule.nctId: "NCT06093841"
protocolSection.identificationModule.officialTitle: "Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.